Australia's largest stock trading and investment forum Australia's #1 stock forum

CDX

2.99%

6.5¢ cardiex limited

Thanks guys. Lazy of me I know, but I was doing other things.An...

First 45 Last

Share
Profile

Follow
kickit2me

13,608 Posts.

4839

02/03/21

13:32

Post #: 51451605
Share

Originally posted by Quiltman: ↑

Yes, it is the ATCOR Pulse :

Our launch date for the Pulse remains on track and we’ve already received the first prototypes and test
units in our US and Sydney offices. Our first contracted order of the Pulse will be ~10,000 units. As a
guide to the impact of this new device on the revenues for the Company, our current device sales of
the XCEL central blood pressure monitor (which constitutes the most significant portion of our sales)
are in the low hundreds annually

A reminder from the ASX release about Andon and Atcor Pulse :

The first device under the Agreement to be named ATCOR “Pulse” (the Device) and will be
targeted for commercial launch in the US, Europe, Australia and China in Q4 2021.

ATCOR “Pulse” will be the first new medical device for ATCOR since 2012 and represents a
game changing medical technology collaboration for home-use vital signs monitoring. This
unique device will be the world’s first cloud-connected home-use BP monitor to include
ATCOR’s SphygmoCor® technology and Arty™, ATCOR’s new cardiovascular vital signs and
telehealth platform (Arty™ being an anagram of “Heart” and “Artery”).

The Agreement with Andon in conjunction with the ATCOR “Pulse” device significantly
expands the commercial market opportunity for CardieX into the home consumer health
device market, which is estimated to be worth $US2.5B annually (Source: Fortune Business
Insight).

When paired with ATCOR’s Arty™ app, the Device will provide full remote patient monitoring
of a patient’s vital signs at home. The remote patient monitoring market is estimated to
reach $US43B by 2027 (Source: 2020 Research & Markets Report).

At launch, the device and will also be fully telehealth-enabled with video, chat, messaging,
customizable screens and full vital signs sharing features between clinician and patient when
paired with the Company’s Arty™ app. ATCOR Pulse will be the first blood pressure device
ever to feature customizable screens and vital signs modules when integrated with the
Company’s new Arty™ app.

Expand

Thanks guys. Lazy of me I know, but I was doing other things.

An announcement late this year of the Pulse Launch along with a confirmed order should move the SP significantly.

Of course the launch of the Mobvoi wearable six months earlier than that will already have the SP above where it is now.

Going to be a great year for Cardiex - meanwhile CC is whipping the Atcor division to increase their revenues as well

...

CDX Price at posting: 8.3¢ Sentiment: Buy Disclosure: Held
6 Upvote

0 Great analysis

Reply

Top Stories

ATH

Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability

LRL

Labyrinth shares rocket by 219% on news of Comet Vale and Vivien gold project acquisitions

NWC

New World Resources inks complete PFS for Antler Copper Project in Arizona, USA

CTT

Cettire shares jump on FY24 revenue growth up 80% vs pcp – but stock still badly bruised

AI stocks: What to expect in 2024-25

There are more pages in this discussion • 2 more messages in this thread...

First 45 Last

Add CDX (ASX) to my watchlist

(20min delay)
Last 6.5¢		Change -0.002(2.99%)		Mkt cap ! $19.12M

Open	High	Low	Value	Volume
6.7¢	6.7¢	6.5¢	$5.286K	80.87K

Buyers (Bids)

No.	Vol.	Price($)
2	38437	6.4¢

Sellers (Offers)

Price($)	Vol.	No.
6.5¢	204834	1

View Market Depth

No.	Vol.	Price($)
2	38437	0.064
1	100000	0.063
4	282076	0.062
1	120000	0.061
2	218000	0.060

Price($)	Vol.	No.
0.065	204834	1
0.066	40900	1
0.067	21625	1
0.068	200000	2
0.069	145000	1

Last trade - 16.10pm 17/07/2024 (20 minute delay)

CDX (ASX) Chart

Thanks guys. Lazy of me I know, but I was doing other things.An...

Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability

Labyrinth shares rocket by 219% on news of Comet Vale and Vivien gold project acquisitions

New World Resources inks complete PFS for Antler Copper Project in Arizona, USA

Cettire shares jump on FY24 revenue growth up 80% vs pcp – but stock still badly bruised

AI stocks: What to expect in 2024-25

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Thanks guys. Lazy of me I know, but I was doing other things.An...

Top Stories

Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability

Labyrinth shares rocket by 219% on news of Comet Vale and Vivien gold project acquisitions

New World Resources inks complete PFS for Antler Copper Project in Arizona, USA

Cettire shares jump on FY24 revenue growth up 80% vs pcp – but stock still badly bruised

AI stocks: What to expect in 2024-25

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News